BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reino JG, Loza E, Andreu JL, Balsa A, Batlle E, Cañete JD, Collantes Estévez E, Fernández Carballido C, Fernández Sueiro JL, García de Vicuña R, González-álvaro I, González Fernández C, Juanola X, Linares LF, Marenco JL, Martín Mola E, Moreno Ramos M, Mulero Mendoza J, Muñoz Fernández S, Queiro R, Richi Alberti P, Sanz J, Tornero Molina J, Zarco Montejo P, Carmona L. Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas. Reumatología Clínica 2011;7:284-98. [DOI: 10.1016/j.reuma.2011.05.002] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Martinez-Santana V, Rodriguez-Murphy E, Smithson A, Miserachs-Aranda N, Del Río-Gil R, Torre-Lloverás I. Efficacy and safety of direct-acting antiviral agents when combined with secukinumab. Eur J Hosp Pharm 2018;25:53-6. [PMID: 31156986 DOI: 10.1136/ejhpharm-2017-001212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Peremiquel-trillas P, Leguízamo LM, Asensio Ostos C, Martínez-gómez X. Vacunas para pacientes en tratamiento con fármacos inmunodepresores, inmunomoduladores o biológicos. Medicina Clínica 2018;151:498-502. [DOI: 10.1016/j.medcli.2018.05.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Papadopoulou D, Sipsas NV. Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. Rheumatol Int 2014;34:151-63. [PMID: 24322451 DOI: 10.1007/s00296-013-2907-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
4 Muñoz-Fernández S, Aguilar MD, Almodóvar R, Cano-García L, Fortea S, Alcañiz-Escandell CP, Rodríguez JR, Cebrián L, Lázaro P; Representing the SCORE working group. SCORE study: quality indicators for rheumatology nursing clinics. Rheumatol Int 2017;37:353-61. [PMID: 28108765 DOI: 10.1007/s00296-016-3644-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Martín Mola E, Balsa A, Martínez Taboada V, Sanmartí R, Marenco JL, Navarro Sarabia F, Gómez-Reino J, Alvaro-Gracia JM, Román Ivorra JA, Lojo L, Plasencia C, Carmona L; Spanish expert panel of rheumatologists. Abatacept use in rheumatoid arthritis: evidence review and recommendations. Reumatol Clin 2013;9:5-17. [PMID: 22766432 DOI: 10.1016/j.reuma.2012.05.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
6 Muñoz-Fernández S, Bustabad Reyes MS, Calvo Alén J, Castaño Sánchez M, Chamizo Carmona E, Corominas H, Fernández-Llanio Comella N, Hidalgo Calleja MC, Pérez Venegas JJ, Rodríguez Heredia JM, Romero Yuste SM, Ruiz-Esquide Torino V; Grupo de trabajo ACORDAR 2015. Biologic Disease-modifying antirheumatic drug attributes in the first lines of treatment of rheumatoid arthritis. 2015 ACORDAR project. Reumatol Clin (Engl Ed) 2018;14:90-6. [PMID: 28065486 DOI: 10.1016/j.reuma.2016.10.001] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Calvo-alén J, Silva-fernández L, Úcar-angulo E, Pego-reigosa JM, Olivé A, Martínez-fernández C, Martínez-taboada V, Luis Marenco J, Loza E, López-longo J, Gómez-reino JJ, Galindo-izquierdo M, Fernández-nebro A, Cuadrado MJ, Aguirre-zamorano MÁ, Zea-mendoza A, Rúa-figueroa Í. Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico. Reumatología Clínica 2013;9:281-96. [DOI: 10.1016/j.reuma.2013.04.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
8 Lopez-Olivo MA, Colmegna I, Karpes Matusevich AR, Qi SR, Zamora NV, Sharma R, Pratt G, Suarez-Almazor ME. Systematic Review of Recommendations on the Use of Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Cancer. Arthritis Care Res (Hoboken) 2020;72:309-18. [PMID: 30821928 DOI: 10.1002/acr.23865] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
9 Saavedra Salinas MÁ, Barrera Cruz A, Cabral Castañeda AR, Jara Quezada LJ, Arce-salinas CA, Álvarez Nemegyei J, Fraga Mouret A, Orozco Alcalá J, Salazar Páramo M, Cruz Reyes CV, Andrade Ortega L, Vera Lastra OL, Mendoza Pinto C, Sánchez González A, Cruz Cruz PDR, Morales Hernández S, Portela Hernández M, Pérez Cristóbal M, Medina García G, Hernández Romero N, Velarde Ochoa MDC, Navarro Zarza JE, Portillo Díaz V, Vargas Guerrero A, Goycochea Robles MV, García Figueroa JL, Barreira Mercado E, Amigo Castañeda MC. Guías de práctica clínica para la atención del embarazo en mujeres con enfermedades reumáticas autoinmunes del Colegio Mexicano de Reumatología. Parte II. Reumatología Clínica 2015;11:305-15. [DOI: 10.1016/j.reuma.2014.12.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
10 Forero E, Chalem M, Vásquez G, Jauregui E, Medina LF, Pinto Peñaranda LF, Medina J, Medina Y, Jaimes D, Arbelaez AM, Domínguez AM, Fernández A, Felipe-díaz OJ, Chalem P, Caballero Uribe CV, Jannaut MJ, García I, Bautista W, Ramírez Figueroa J, Cortés J, Quintero J, Rodríguez N. Gestión de riesgo para la prescripción de terapias biológicas. Revista Colombiana de Reumatología 2016;23:50-67. [DOI: 10.1016/j.rcreu.2016.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Hernández MV, Sanmartí R, Cañete JD. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Expert Opin Drug Saf 2016;15:613-24. [PMID: 26927029 DOI: 10.1517/14740338.2016.1160054] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
12 Vidal Alejandre B, Tovar Sugrañes E, López Poza R, Andrés M, Martínez-Vidal MP. Human papilloma virus screening: evaluation of testing and surveillance in rheumatoid arthritis, psoriatic arthritis and systemic lupus erythematosus. Reumatol Clin (Engl Ed) 2021;17:494-8. [PMID: 34756309 DOI: 10.1016/j.reumae.2020.05.007] [Reference Citation Analysis]
13 Cobo-Ibáñez T, Descalzo MÁ, Loza-Santamaría E, Carmona L, Muñoz-Fernández S. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. Rheumatol Int 2014;34:953-61. [PMID: 24414744 DOI: 10.1007/s00296-014-2945-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
14 Bernal JA, Andrés M, Jovaní V, García Sevila R, Begazo A, Vela P. Primary tuberculosis infection in patients treated with tumor necrosis factor-alpha antagonists and a negative initial screening. Reumatol Clin 2016;12:81-4. [PMID: 26099453 DOI: 10.1016/j.reuma.2015.04.001] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
15 González-Álvaro I, Martínez-Fernández C, Dorantes-Calderón B, García-Vicuña R, Hernández-Cruz B, Herrero-Ambrosio A, Ibarra-Barrueta O, Martín-Mola E, Monte-Boquet E, Morell-Baladrón A, Sanmartí R, Sanz-Sanz J, de Toro-Santos FJ, Vela P, Román Ivorra JA, Poveda-Andrés JL, Muñoz-Fernández S; Spanish Rheumatology Society., Spanish Rheumatology Society. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford) 2015;54:1200-9. [PMID: 25526976 DOI: 10.1093/rheumatology/keu461] [Cited by in Crossref: 49] [Cited by in F6Publishing: 23] [Article Influence: 6.1] [Reference Citation Analysis]
16 Frías-Vargas M, Aguado-Castaño AC, Robledo-Orduña C, García-Lerín A, González-Gay MÁ, García-Vallejo O; en nombre del Grupo de Trabajo Vasculopatías SEMERGEN. [Giant Cell Arteritis. Recommendations in Primary Care]. Semergen 2021;47:256-66. [PMID: 34112594 DOI: 10.1016/j.semerg.2021.04.002] [Reference Citation Analysis]
17 Calvo-alén J, Silva-fernández L, Úcar-angulo E, Pego-reigosa JM, Olivé A, Martínez-fernández C, Martínez-taboada V, Marenco JL, Loza E, López-longo J, Gómez-reino JJ, Galindo-izquierdo M, Fernández-nebro A, Cuadrado MJ, Aguirre-zamorano MÁ, Zea-mendoza A, Rúa-figueroa Í. SER Consensus Statement on the Use of Biologic Therapy for Systemic Lupus Erythematosus. Reumatología Clínica (English Edition) 2013;9:281-96. [DOI: 10.1016/j.reumae.2013.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Loza E, Lajas C, Andreu JL, Balsa A, González-Álvaro I, Illera O, Jover JÁ, Mateo I, Orte J, Rivera J, Rodríguez Heredia JM, Romero F, Martínez-López JA, Ortiz AM, Toledano E, Villaverde V, Carmona L, Castañeda S. Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. Rheumatol Int 2015;35:445-58. [PMID: 25543267 DOI: 10.1007/s00296-014-3196-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
19 Schlueter M, Finn E, Díaz S, Dilla T, Inciarte-Mundo J, Fakhouri W. Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain. Clinicoecon Outcomes Res 2019;11:395-403. [PMID: 31239736 DOI: 10.2147/CEOR.S201621] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
20 Torre-alonso JC, Carmona L, Moreno M, Galíndez E, Babío J, Zarco P, Linares L, Collantes-estevez E, Barrial MF, Hermosa JC, Coto P, Suárez C, Almodóvar R, Luelmo J, Castañeda S, Gratacós J. Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain. Rheumatol Int 2017;37:1239-48. [DOI: 10.1007/s00296-017-3702-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
21 Vidal Alejandre B, Tovar Sugrañes E, López Poza R, Andrés M, Martínez-Vidal MP. Human Papiloma Virus Screening: Evaluation Of Testing And Surveillance In Rheumatoid Arthritis, Psoriatic Arthritis And Systemic Lupus Erythematosus. Reumatol Clin (Engl Ed) 2020:S1699-258X(20)30135-2. [PMID: 32709510 DOI: 10.1016/j.reuma.2020.05.007] [Reference Citation Analysis]
22 Muñoz-Fernández S, Aguilar MD, Rodríguez A, Almodóvar R, Cano-García L, Gracia LA, Román-Ivorra JA, Rodríguez JR, Navío T, Lázaro P; SCORE Working Group. Evaluation of the impact of nursing clinics in the rheumatology services. Rheumatol Int 2016;36:1309-17. [PMID: 27435921 DOI: 10.1007/s00296-016-3518-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
23 Cañete JD, Hernández MV, Sanmartí R. Safety profile of biological therapies for treating rheumatoid arthritis. Expert Opinion on Biological Therapy 2017;17:1089-103. [DOI: 10.1080/14712598.2017.1346078] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
24 Martínez López JA, García Vivar ML, Cáliz R, Freire M, Galindo M, Hernández MV, López Longo FJ, Martínez Taboada V, Pego Reigosa JM, Rubio E, Trujillo E, Vela-Casasempere P. Recommendations for the evaluation and management of patients with rheumatic autoimmune and inflammatory diseases during the reproductive age, pregnancy, postpartum and breastfeeding. Reumatol Clin 2017;13:264-81. [PMID: 27321859 DOI: 10.1016/j.reuma.2016.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
25 Reina D, Cerdà D, Güell E, Martínez Montauti J, Pineda A, Corominas H. Kala-azar en un paciente con artritis reumatoide tratada con metotrexato. Reumatología Clínica 2017;13:354-6. [DOI: 10.1016/j.reuma.2016.07.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]